Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies.

Pietsch EC, Dong J, Cardoso R, Zhang X, Chin D, Hawkins R, Dinh T, Zhou M, Strake B, Feng PH, Rocca M, Santos CD, Shan X, Danet-Desnoyers G, Shi F, Kaiser E, Millar HJ, Fenton S, Swanson R, Nemeth JA, Attar RM.

Blood Cancer J. 2017 Feb 24;7(2):e536. doi: 10.1038/bcj.2017.7.

2.

Tumor-associated macrophages promote invasion while retaining Fc-dependent anti-tumor function.

Grugan KD, McCabe FL, Kinder M, Greenplate AR, Harman BC, Ekert JE, van Rooijen N, Anderson GM, Nemeth JA, Strohl WR, Jordan RE, Brezski RJ.

J Immunol. 2012 Dec 1;189(11):5457-66. doi: 10.4049/jimmunol.1201889. Epub 2012 Oct 26.

3.

Cyclophosphamide creates a receptive microenvironment for prostate cancer skeletal metastasis.

Park SI, Liao J, Berry JE, Li X, Koh AJ, Michalski ME, Eber MR, Soki FN, Sadler D, Sud S, Tisdelle S, Daignault SD, Nemeth JA, Snyder LA, Wronski TJ, Pienta KJ, McCauley LK.

Cancer Res. 2012 May 15;72(10):2522-32. doi: 10.1158/0008-5472.CAN-11-2928.

4.

Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma.

Hunsucker SA, Magarotto V, Kuhn DJ, Kornblau SM, Wang M, Weber DM, Thomas SK, Shah JJ, Voorhees PM, Xie H, Cornfeld M, Nemeth JA, Orlowski RZ.

Br J Haematol. 2011 Mar;152(5):579-92. doi: 10.1111/j.1365-2141.2010.08533.x. Epub 2011 Jan 17.

5.

JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling.

Song L, Rawal B, Nemeth JA, Haura EB.

Mol Cancer Ther. 2011 Mar;10(3):481-94. doi: 10.1158/1535-7163.MCT-10-0502. Epub 2011 Jan 7.

6.

Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways.

Puhr M, Santer FR, Neuwirt H, Susani M, Nemeth JA, Hobisch A, Kenner L, Culig Z.

Cancer Res. 2009 Sep 15;69(18):7375-84. doi: 10.1158/0008-5472.CAN-09-0806. Epub 2009 Sep 8.

7.

Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death.

Voorhees PM, Chen Q, Small GW, Kuhn DJ, Hunsucker SA, Nemeth JA, Orlowski RZ.

Br J Haematol. 2009 May;145(4):481-90. doi: 10.1111/j.1365-2141.2009.07647.x. Epub 2008 Mar 6.

8.

Circulating human interleukin-8 as an indicator of cancer progression in a nude rat orthotopic human non-small cell lung carcinoma model.

Millar HJ, Nemeth JA, McCabe FL, Pikounis B, Wickstrom E.

Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2180-7. doi: 10.1158/1055-9965.EPI-07-2915.

9.

Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo.

Ning S, Nemeth JA, Hanson RL, Forsythe K, Knox SJ.

Mol Cancer Ther. 2008 Jun;7(6):1569-78. doi: 10.1158/1535-7163.MCT-08-0288.

10.

Mcl-1 is regulated by IL-6 and mediates the survival activity of the cytokine in a model of late stage prostate carcinoma.

Cavarretta IT, Neuwirt H, Zaki MH, Steiner H, Hobisch A, Nemeth JA, Culig Z.

Adv Exp Med Biol. 2008;617:547-55. doi: 10.1007/978-0-387-69080-3_56.

PMID:
18497081
11.

Alpha-v integrins as therapeutic targets in oncology.

Nemeth JA, Nakada MT, Trikha M, Lang Z, Gordon MS, Jayson GC, Corringham R, Prabhakar U, Davis HM, Beckman RA.

Cancer Invest. 2007 Oct;25(7):632-46. Review.

PMID:
18027153
12.

Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.

Voorhees PM, Chen Q, Kuhn DJ, Small GW, Hunsucker SA, Strader JS, Corringham RE, Zaki MH, Nemeth JA, Orlowski RZ.

Clin Cancer Res. 2007 Nov 1;13(21):6469-78.

13.

Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors.

Mullamitha SA, Ton NC, Parker GJ, Jackson A, Julyan PJ, Roberts C, Buonaccorsi GA, Watson Y, Davies K, Cheung S, Hope L, Valle JW, Radford JA, Lawrance J, Saunders MP, Munteanu MC, Nakada MT, Nemeth JA, Davis HM, Jiao Q, Prabhakar U, Lang Z, Corringham RE, Beckman RA, Jayson GC.

Clin Cancer Res. 2007 Apr 1;13(7):2128-35.

14.

The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1.

Cavarretta IT, Neuwirt H, Untergasser G, Moser PL, Zaki MH, Steiner H, Rumpold H, Fuchs D, Hobisch A, Nemeth JA, Culig Z.

Oncogene. 2007 May 3;26(20):2822-32. Epub 2006 Oct 30.

PMID:
17072336
15.

Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328.

Steiner H, Cavarretta IT, Moser PL, Berger AP, Bektic J, Dietrich H, Zaki MH, Nakada M, Hobisch A, Nemeth JA, Culig Z.

Prostate. 2006 Dec 1;66(16):1744-52.

PMID:
16998813
16.
17.

Absence of adverse effects in cynomolgus macaques treated with CNTO 95, a fully human anti-alphav integrin monoclonal antibody, despite widespread tissue binding.

Martin PL, Jiao Q, Cornacoff J, Hall W, Saville B, Nemeth JA, Schantz A, Mata M, Jang H, Fasanmade AA, Anderson L, Graham MA, Davis HM, Treacy G.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6959-65.

18.

CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice.

Zaki MH, Nemeth JA, Trikha M.

Int J Cancer. 2004 Sep 10;111(4):592-5.

19.

CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo.

Trikha M, Zhou Z, Nemeth JA, Chen Q, Sharp C, Emmell E, Giles-Komar J, Nakada MT.

Int J Cancer. 2004 Jun 20;110(3):326-35.

20.

Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases.

Nemeth JA, Cher ML, Zhou Z, Mullins C, Bhagat S, Trikha M.

Clin Exp Metastasis. 2003;20(5):413-20.

PMID:
14524530
21.

Scalp burns from halo pins following magnetic resonance imaging. Case illustration.

Kim LJ, Sonntag VK, Hott JT, Nemeth JA, Klopfenstein JD, Tweardy L.

J Neurosurg. 2003 Jul;99(1):186. No abstract available.

PMID:
12854765
22.

Role for beta3 integrins in human melanoma growth and survival.

Trikha M, Timar J, Zacharek A, Nemeth JA, Cai Y, Dome B, Somlai B, Raso E, Ladanyi A, Honn KV.

Int J Cancer. 2002 Sep 10;101(2):156-67.

23.

Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis.

Nemeth JA, Yousif R, Herzog M, Che M, Upadhyay J, Shekarriz B, Bhagat S, Mullins C, Fridman R, Cher ML.

J Natl Cancer Inst. 2002 Jan 2;94(1):17-25.

PMID:
11773278
24.

Proliferation of prostate cancer cells in the bone marrow predicts recurrence in patients with localized prostate cancer.

Bianco FJ Jr, Wood DP Jr, Gomes de Oliveira J, Nemeth JA, Beaman AA, Cher ML.

Prostate. 2001 Dec 1;49(4):235-42.

PMID:
11746269
25.
26.

Persistence of human vascular endothelium in experimental human prostate cancer bone tumors.

Nemeth JA, Roberts JW, Mullins CM, Cher ML.

Clin Exp Metastasis. 2000;18(3):231-7.

PMID:
11315096
27.

Six-pin halo fixation and the resulting prevalence of pin-site complications.

Nemeth JA, Mattingly LG.

J Bone Joint Surg Am. 2001 Mar;83(3):377-82.

PMID:
11263641
28.
29.
30.

Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia.

Upadhyay J, Shekarriz B, Nemeth JA, Dong Z, Cummings GD, Fridman R, Sakr W, Grignon DJ, Cher ML.

Clin Cancer Res. 1999 Dec;5(12):4105-10.

31.

Cellular proliferation and prevalence of micrometastatic cells in the bone marrow of patients with clinically localized prostate cancer.

Cher ML, de Oliveira JG, Beaman AA, Nemeth JA, Hussain M, Wood DP Jr.

Clin Cancer Res. 1999 Sep;5(9):2421-5.

32.

Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone.

Nemeth JA, Harb JF, Barroso U Jr, He Z, Grignon DJ, Cher ML.

Cancer Res. 1999 Apr 15;59(8):1987-93.

33.

The primary culture of rat prostate basal cells.

Ilio KY, Nemeth JA, Lang S, Lee C.

J Androl. 1998 Nov-Dec;19(6):718-24.

34.

Keratinocyte growth factor in the rat ventral prostate: androgen-independent expression.

Nemeth JA, Zelner DJ, Lang S, Lee C.

J Endocrinol. 1998 Jan;156(1):115-25.

PMID:
9496241
35.

Prostatic ductal system in rats: tissue-specific expression and regional variation in stromal distribution of transforming growth factor-beta 1.

Nemeth JA, Sensibar JA, White RR, Zelner DJ, Kim IY, Lee C.

Prostate. 1997 Sep 15;33(1):64-71.

PMID:
9294629
36.

Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues.

Kim IY, Ahn HJ, Zelner DJ, Shaw JW, Lang S, Kato M, Oefelein MG, Miyazono K, Nemeth JA, Kozlowski JM, Lee C.

Clin Cancer Res. 1996 Aug;2(8):1255-61.

37.

TIMP-2 growth-stimulatory activity: a concentration- and cell type-specific response in the presence of insulin.

Nemeth JA, Rafe A, Steiner M, Goolsby CL.

Exp Cell Res. 1996 Apr 10;224(1):110-5.

PMID:
8612674
38.

Prostatic ductal system in rats: regional variation in stromal organization.

Nemeth JA, Lee C.

Prostate. 1996 Feb;28(2):124-8.

PMID:
8604393
39.

TIMP-2, a growth-stimulatory protein from SV40-transformed human fibroblasts.

Nemeth JA, Goolsby CL.

Exp Cell Res. 1993 Aug;207(2):376-82.

PMID:
8393803

Supplemental Content

Loading ...
Support Center